Researcher.Life Logo

Therapeutic Advances in Musculoskeletal Disease : Impact Factor & More

eISSN: 1759-7218pISSN: 1759-720X
JournalOpen Access

Key Metrics

CiteScore
3.7
H-Index
44
Impact Factor
< 5
SJR
Q1Rheumatology
SNIP
1.17
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Therapeutic Advances in Musculoskeletal Disease

Therapeutic Advances in Musculoskeletal Disease Journal Specifications

Overview
Publisher SAGE PUBLICATIONS LTD
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2300
Publication Time18
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2009
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 18
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Therapeutic Advances in Musculoskeletal Disease ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Therapeutic Advances in Musculoskeletal Disease

Early identification of difficult-to-manage axial spondyloarthritis using machine-learning decision trees
  • 16 Jun 2026
  • Therapeutic Advances in Musculoskeletal Disease
Patients with poorer health status are more likely to have difficult-to-manage axial spondyloarthritis: insights from a real-world cohort
  • 14 Jun 2026
  • Therapeutic Advances in Musculoskeletal Disease
Development and validation of a clinical scoring system for the prediction of methotrexate treatment response in rheumatoid arthritis patients: a multicenter real-world study
  • 10 Jun 2026
  • Therapeutic Advances in Musculoskeletal Disease
Towards an individualised approach to pain management in inflammatory arthritis
  • 9 Jun 2026
  • Therapeutic Advances in Musculoskeletal Disease
Mapping emotional function in fibromyalgia: integrating alexithymia, pain catastrophizing, and self-compassion
  • 1 Jun 2026
  • Therapeutic Advances in Musculoskeletal Disease
Incidence of interstitial lung disease in seropositive rheumatoid arthritis patients receiving biologics, Janus kinase inhibitors, or methotrexate
  • 28 May 2026
  • Therapeutic Advances in Musculoskeletal Disease
Early identification of difficult-to-manage axial spondyloarthritis using machine-learning decision trees
  • 16 Jun 2026
  • Therapeutic Advances in Musculoskeletal Disease
Patients with poorer health status are more likely to have difficult-to-manage axial spondyloarthritis: insights from a real-world cohort
  • 14 Jun 2026
  • Therapeutic Advances in Musculoskeletal Disease
Development and validation of a clinical scoring system for the prediction of methotrexate treatment response in rheumatoid arthritis patients: a multicenter real-world study
  • 10 Jun 2026
  • Therapeutic Advances in Musculoskeletal Disease
Towards an individualised approach to pain management in inflammatory arthritis
  • 9 Jun 2026
  • Therapeutic Advances in Musculoskeletal Disease
Mapping emotional function in fibromyalgia: integrating alexithymia, pain catastrophizing, and self-compassion
  • 1 Jun 2026
  • Therapeutic Advances in Musculoskeletal Disease
Incidence of interstitial lung disease in seropositive rheumatoid arthritis patients receiving biologics, Janus kinase inhibitors, or methotrexate
  • 28 May 2026
  • Therapeutic Advances in Musculoskeletal Disease

FAQs on Therapeutic Advances in Musculoskeletal Disease